22 04 08 CS MEDICA introduces monthly letter from the CEO

CS MEDICA introduces monthly letter from the CEO

CS MEDICA’s (”CS MEDICA” or the ”Company”) are now introducing a monthly CEO letter with the intention to keep shareholders and other interested parties updated about the Company’s expected objectives and activities in the forthcoming month. The CEO letter will cover important events, status in development and touch upon current events within the Company’s industry and field of business.

As a first mover within medical treatment with cannabinoids, it requires huge dedication, persistence, focus and aspirations from our employees to build and maintain momentum within our field of business. To keep our shareholders updated, we are now introducing our monthly CEO letter going forward.

In CS MEDICA we are driven by making the best cannabis medical products in the world. Our goal is to become a leading company in the cannabis medical treatment industry, and we truly believe we are going to change the millions of people life’s who buy our products.  With the introduction of CANNASEN® CBD product line, we are positioned at the forefront and are currently the only company delivering medical products based on cannabinoids under the pharmaceutical legislation. The competitive advantage that truly distinguishes CS MEDICA is that the Company’s product offering is positioned at the intersection of natural products, science, and cannabinoid technology, while also working under the pharmaceutical legislation (MDR). Bringing these aspirations together – is what drives us.

Our philosophy and focus on the safety and efficacy proven under the pharmaceutical legislation are now paying off. Currently, an intensified global focus is directed on cannabis products not meeting the now stricter requirements under the pharmaceutical legislation.  Consequently, there is a general withdrawal of illegal cannabis products, leaving only prescription medicine and medical and cosmetic products, like ours, on the market. In the UK[1], thousands of cannabis products that do not comply with FSA(UK) requirements are now being removed from the shelves. In addition, in Hong Kong, the customs just seized cannabidiol products containing tetrahydro-cannabinol (THC) worth about $14.6 million[2].

Despite these incidents, the interest in cannabinoid medical products is increasing and BIG pharma is now breaking ground in the escalating cannabinoids industry.  Most recently, the fourth acquisition within BIG Pharma was completed by INDIA’S fourth largest pharmaceutical company, Dr Reddy’s Labs, with their purchase of the German cannabis product whole seller, Nimbus Health. In December, Pfizer announced its acquisition of Arena Pharmaceutical, a medical cannabis company, for $6.7 billion. In May last year, Jazz Pharma bought GW Pharma, a maker of cannabis medications. In 2019, generic major Teva Pharma signed a distribution deal with Israeli medical marijuana company Canndoc.

Objectives and activities in April

Distributor sale (Cannordic): We are continuously working with our all-encompassing process moving from being a fully R&D-centric company to becoming more sales-focused. We hired our new Chief Growth Officer who we believe will accelerate and add further value to our global rollout. For April, we will continue to evaluate potential distributions contracts and aim to go through with the following processes:

  • a cooperation agreement within White Label
  • launch of several Amazon platforms

Btc channel sales (Galaxa Pharma): At this time, we have more than 500 sales channels in the Nordic area with more to come. We are now experiencing a growing interest in our product line, among others originating from our planned post-marketing clinical trials in local disease organization. In April the following agreements and CANNASEN® CBD product releases and launches are expected;

  • Launch  –  Dinapoteker.dk- online
    Psoriasis, Arthritis, Anti-Hair loss Serum, Pain Patch, Protective nasal gel, PSOR + ATOPIC lotion
  • Launch  –  Webapoteket.dk & Apopro.dk- online
    Pain Patch, Protective nasal gel, PSOR + ATOPIC lotion
  • Launch  –  on Matas.dk – online +expectedly on shelf
    Protective nasal gel
  • Launch   – Apotekeren.dk + landing page
    Psoriasis, Arthritis, Anti-Hair loss Serum, Pain Patch, Protective nasal gel, PSOR + ATOPIC lotion
  • Launch  – cannasen.dk – brand web shop
    All CANNASEN® CBD products

Clinical trials: All CS MEDICA’s medical products are registered under the pharmaceutical legislation Medical Device Directive (MDD) currently under update to the new Medical Device Regulation (MDR). The following clinical trial phases are planned to be finalised in April;

Clinical trial – phase III

  • Arthritis gel versus Placebo
  • Arthritis gel & Arthritis Caps versus Arthritis gel & Placebo Caps

Furthermore, we expect to have our “1/billion no trace of THC test” (PPB test, Parts-Per-Billion) finalized in order to enter the Asian market.

IPR rights: All medical products from CS MEDICA are IPR secured by patents and trademarks. In April the following phases are met;

Patent Arthritis and psoriasis – lifted to Phase III
Patent is continued from Phase II PCT (155 countries in the world) to Phase III (final Phase), with the following locale areas filed:  Australia, Canada, Europe, Japan, New Zealand, USA, India, China, South Korea, Israel

Patent – lifted to Phase II
Patent is continued from phase I (DK) to phase II – PCT (155 countries in the world)

  • Arthritis and psoriasis in combination with supplements
  • CBD hair serum
  • Nasal Spray night
  • Wound treatment
  • Pain Patch
  • Protective Nasal gel

Technology: Our CIM (Clinical Information Management system) goes live in beta version and preparation of marketing presentation will be initiated.  After finalising this phase, the CIM will be used for initiating post-marketing clinical trials together with local disease organisations, starting with a minor organisation to test the first version after beta.

Our PIM (Product Information management system) goes live in the updated version.


Hope you enjoyed this first CEO letter.  We are looking forward to keeping you updated with our company’s industry and field of business in future CEO letters.


[1] https://businesscann.com/one-year-late-the-fsa-publishes-list-of-eligible-uk-cbd-products-for-now/


For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.